Literature DB >> 26468002

Prevalence and determinants of unintended double medication of antihypertensive, lipid-lowering, and hypoglycemic drugs in Austria: a nationwide cohort study.

Georg Heinze1, Lisanne M Jandeck1, Milan Hronsky1, Berthold Reichardt2, Christoph Baumgärtel3, Anna Bucsics4,5, Marcus Müllner3,6, Wolfgang C Winkelmayer7,8.   

Abstract

PURPOSE: Double medication is defined as the unintended overlapping prescription of two identical substances with the same route of administration by two different prescribers to the same patient. Consequences of double medication are reduced patient safety and excess healthcare costs. Based on nationwide prescription data from 2011 covering 97% of Austria's population, we estimated double medication prevalences for treatment of hypertension, hyperlipidemia, and diabetes mellitus.
METHODS: We investigated prescriptions of 88 antihypertensive, 16 lipid-lowering and 29 hypoglycemic substances in 7,971,323 persons in 2011. Prevalence of double medication was calculated patientwise (prevalence by patients) and timewise (prevalence by patient-years). Risk factors for double medication were identified by logistic regression.
RESULTS: For antihypertensive, lipid-lowering, and hypoglycemic subtances, overall 15.0% (men: 15.1%, women: 15.0%), 13.1% (13.7%, 12.5%), and 13.0% (13.0%, 13.4%) of patients were doubly medicated, respectively. Corresponding prevalences by patient-years were 1.6%, 2.0%, and 1.2%. Logistic regression confirmed lower age and copayment waiver as independent risk factors of double medication. Furthermore, double medication occurred more often with prescriptions from hospitals or internal medicine specialists compared with general practitioners, as well as in August compared with earlier or later in the calendar year.
CONCLUSION: While appropriate care or comanagement of patients by internal medicine specialists and general practitioners may explain some of the double prescriptions, our data indicate that unintended double medication is frequent. In Austria, lack of financial incentives of patients to avoid filling duplicate prescriptions explains a considerable fraction of double medication occurrences.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  anatomical therapeutic chemical (ATC) classification system; diabetes mellitus; drug utilization; duplicate prescription; hyperlipidemia; hypertension; pharmacoepidemiology

Mesh:

Substances:

Year:  2015        PMID: 26468002     DOI: 10.1002/pds.3898

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  4 in total

1.  Therapeutic Duplicates in a Cohort of Hospitalized Elderly Patients: Results from the REPOSI Study.

Authors:  Luca Pasina; Sarah Astuto; Laura Cortesi; Mauro Tettamanti; Carlotta Franchi; Alessandra Marengoni; Pier Mannuccio Mannucci; Alessandro Nobili
Journal:  Drugs Aging       Date:  2016-09       Impact factor: 3.923

2.  Drug-related problems in community-dwelling primary care patients screened positive for dementia.

Authors:  D Wucherer; J R Thyrian; T Eichler; J Hertel; I Kilimann; S Richter; B Michalowsky; I Zwingmann; A Dreier-Wolfgramm; C A Ritter; S Teipel; W Hoffmann
Journal:  Int Psychogeriatr       Date:  2017-08-07       Impact factor: 3.878

3.  The role of prescription drugs in female overactive bladder syndrome-A population-wide cohort study.

Authors:  Wolfgang Umek; Andreas Gleiss; Barbara Bodner-Adler; Berthold Reichardt; Christoph Rinner; Georg Heinze
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-12-05       Impact factor: 2.890

4.  Using Background Knowledge from Preceding Studies for Building a Random Forest Prediction Model: A Plasmode Simulation Study.

Authors:  Lorena Hafermann; Nadja Klein; Geraldine Rauch; Michael Kammer; Georg Heinze
Journal:  Entropy (Basel)       Date:  2022-06-20       Impact factor: 2.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.